Journal ArticleDOI
Best Supportive Care Compared With Chemotherapy for Unresectable Gall Bladder Cancer: A Randomized Controlled Study
Atul Sharma,Amit Dutt Dwary,Bidhu Kalyan Mohanti,Surya V. Deo,Sujoy Pal,V Sreenivas,Vinod Raina,Nootan Kumar Shukla,Sanjay Thulkar,Pramod Kumar Garg,Surendra Pal Chaudhary +10 more
Reads0
Chats0
TLDR
This randomized controlled trial confirmed the efficacy of chemotherapy (mGEMOX) compared with BSC and FUFA in improving OS and PFS in unresectable GBC.Abstract:
Purpose We designed this study to evaluate efficacy of modified gemcitabine and oxaliplatin (mGEMOX) over best supportive care (BSC) or fluorouracil (FU) and folinic acid (FA) in unresectable gall bladder cancer (GBC). Patients and Methods Patients with unresectable GBC were enrolled for single center randomized study. Arm A, BSC; arm B, FU 425 mg/m2 and FA 20 mg/m2 intravenous (IV) bolus weekly for 30 weeks (FUFA); arm C, gemcitabine 900 mg/m2 and oxaliplatin 80 mg/m2 IV infusion on days 1 and 8 every 3 weeks for maximum of six cycles. Eighty-one patients were randomly assigned, arms A (n = 27), B (n = 28), and C (n = 26). Results Complete response plus partial response in the three groups was 0 (0%), four (14.3%), and eight (30.8%) respectively (P < .001). Two patients in the mGEMOX arm and one patient in the FUFA arm underwent curative resection after chemotherapy. One patient in the mGEMOX arm had complete pathologic response. Median overall survival (OS) was 4.5, 4.6, and 9.5 months for the BSC, FUFA...read more
Citations
More filters
Journal ArticleDOI
Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma
John Bridgewater,Peter R. Galle,Shahid A. Khan,Josep M. Llovet,Joong-Won Park,Tushar Patel,Timothy M. Pawlik,Gregory J. Gores +7 more
TL;DR: University College, London Cancer Institute, 72 Huntley St.
Journal ArticleDOI
Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
TL;DR: This report presents the results of a meta-analyses conducted at the 2015 European Oncologia Conference on Gastroenterology and Hepatology/Hematology of Prostate and Digestive Health, held in Brussels, Belgium, which confirmed the need for further studies into the role of EMT in the development of central nervous system disease.
Journal ArticleDOI
Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study
Jeeyun Lee,Se Hoon Park,Heung Moon Chang,Jun Suk Kim,Hye Jin Choi,Myung Ah Lee,Joung Soon Chang,Hei Cheul Jeung,Jung Hun Kang,Hyun Woo Lee,Dong Bok Shin,Hye Jin Kang,Jong Mu Sun,Joon Oh Park,Young Suk Park,Won Ki Kang,Ho Yeong Lim +16 more
TL;DR: Although no significant difference in progression-free survival was noted between groups, the addition of erlotinib to gemcitabine and oxaliplatin showed antitumour activity and might be a treatment option for patients with cholangiocarcinoma.
Journal ArticleDOI
Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial
David Malka,Pascale Cervera,Stéphanie Foulon,Tanja Trarbach,Christelle De La Fouchardiere,Eveline Boucher,Laetitia Fartoux,Sandrine Faivre,Jean-Frédéric Blanc,Frédéric Viret,Eric Assenat,Thomas Seufferlein,Thomas Herrmann,Julien Grenier,Pascal Hammel,Matthias M. Dollinger,Thierry André,Philipp Hahn,Volker Heinemann,Vanessa Rousseau,Michel Ducreux,Jean-Pierre Pignon,Dominique Wendum,Olivier Rosmorduc,Tim F. Greten +24 more
TL;DR: The addition of cetuximab to gemcitabine and oxaliplatin did not seem to enhance the activity of chemotherapy in patients with advanced biliary cancer, although it was well tolerated.
Journal ArticleDOI
Cisplatin and gemcitabine for advanced biliary tract cancer: a meta-analysis of two randomised trials
Juan W. Valle,Junji Furuse,Mark Jitlal,Sandy Beare,Nobumasa Mizuno,Harpreet Wasan,John Bridgewater,Takuji Okusaka +7 more
TL;DR: CisGem is the standard of care for the first-line treatment of good-PS patients with advanced BTC regardless of ethnicity and resulted in improved PFS and OS for intra- and extra-hepatic cholangiocarcinomas and gallbladder cancer.
References
More filters
Journal ArticleDOI
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
Juan Ignacio Valle,Harpreet Wasan,Daniel H. Palmer,David Cunningham,Alan Anthoney,Anthony Maraveyas,Srinivasan Madhusudan,Timothy Iveson,Sharon M. Hughes,Stephen P. Pereira,M Roughton,John Bridgewater +11 more
TL;DR: Cisplatin plus gemcitabine is an appropriate option for the treatment of patients with advanced biliary cancer and was associated with a significant survival advantage without the addition of substantial toxicity.
Journal ArticleDOI
Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer
Bengt Glimelius,Katarina Hoffman,P.O. Sjödén,G. Jacobsson,H Sellstrom,L-K Enander,Thomas Linne,C Svensson +7 more
TL;DR: The results show that chemotherapy can add to both quantity and quality of life in advanced pancreatic and biliary cancer.
Journal ArticleDOI
Epidemiology and molecular pathology of gallbladder cancer.
Eduardo Lazcano-Ponce,Juan Miquel,Nubia Muñoz,Rolando Herrero,Catterina Ferrecio,Ignacio Ivan Wistuba,Patricia Alonso de Ruiz,Gerardo Aristi Urista,Flavio Nervi +8 more
TL;DR: The worldwide geographical distribution of gallbladder cancer is reported, the main etiologic hypotheses are reviewed, and some comments on perspectives for prevention are provided.
Journal ArticleDOI
Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer
Jochen Weigt,Peter Malfertheiner +1 more
TL;DR: Cisplatin plus gemcitabine, compared with gem citabine alone, was associated with a significant survival advantage without an increase in substantial toxicity.
Journal ArticleDOI
Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study
Thierry André,Christophe Tournigand,Olivier Rosmorduc,S. Provent,F. Maindrault-Goebel,D. Avenin,Frédéric Selle,François Paye,Laurent Hannoun,Houry S,Brice Gayet,J. P. Lotz,A. de Gramont,C. Louvet +13 more
TL;DR: The GEMOX combination is active and well tolerated in ABTA and should be used as first-line chemotherapy in advanced biliary tract adenocarcinoma patients.
Related Papers (5)
Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials
F Eckel,Roland M Schmid +1 more